Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...
Sparad:
Huvudupphovsmän: | , , , , , , , , , , , , , |
---|---|
Materialtyp: | Artikel |
Språk: | engelska |
Publicerad: |
Philipps-Universität Marburg
2023
|
Ämnen: | |
Länkar: | PDF-fulltext |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
No abstracts were found for this record.